## Methods
Parallel group study.
Randomisation: Randomised, double blind, placebo-controlled trial
Trial duration: 24 weeks.
Intention-to-treat analysis: Stated.

## Participants
1) Setting: Not stated.
2) Participants: 518 (Roflumilast 500 μg: 200, Placebo: 280)
3) Baseline characteristics: Mean age: 60 years, 75% male, 62% current smokers. Average of 35 pack years.
4) Inclusion criteria: Aged 40 to 75 years, FEV1/FVC≤0.7. Post-bronchodilator FEV1 35% to 75% of predicted, FEV1 reversibility≤12% and ≤200 mL. Pre-bronchodilator FEV1/FVC≤70%.
5) Exclusion criteria: not stated.
6) Participant withdrawals not stated.

## Interventions
Run in: 2 weeks with placebo.
1) Roflumilast 500 μg once daily for 24 weeks.
2) Roflumilast 500 μg once daily for 12 weeks. Placebo once daily for following 12 weeks.
Concomitant medication
- Short acting anticholinergic: All medications were withdrawn except constant dose short acting anti-cholinergics.
- Short acting β2 agonist: As rescue medication.
- Corticosteroid: None.
- Long acting β2 bronchodilator: None.
Used alongside short acting β2 agonists (available to all).

## Outcomes
Primary Outcomes: Results for 12/24 week post bronchodilator FEV1

## P I C O 및 근거표
### Risk of bias
#### Bias
| | Authors' judgement | Support for judgement |
|---|---|---|
| Allocation concealment (selection bias) | Unclear risk | No information available. |
| Randomised? | Low risk | "After randomisation, patients received placebo or roflumilast 500 μg once daily for 24 weeks or roflumilast 500 μg for 12 weeks followed by placebo for 12 weeks"
| Method of Randomisation described? | High risk | |
| Blinding? | Low risk | Double blinded. |
| Method of Blinding described? | High risk | |
| Description of Withdrawals and Drop outs? | High risk | |

#### Baseline profile:
| | Authors' judgement | Support for judgement |
|---|---|---|
| Anticholinergic use | Unclear risk | No further information available. |
| β2 agonist use | Unclear risk | No further information available. |
| Corticosteroid use | Unclear risk | No information available. |

#### Outcome or subgroup title
| Outcome or subgroup title | Statistical method | Effect size |
|---|---|---|
| FEV1 | Mean Difference (IV, Fixed, 95% CI) | 39.00 [–9.44, 87.44] |

Author, year Rabe F, 2005
Title Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.

## Methods
Parallel group study.
Randomisation: Randomised, double blind, placebo-controlled trial
Trial duration: 24 weeks.
Intention-to-treat analysis: Stated.

## Participants
1) Setting: 159 centres in Australia, Austria, Belgium, Canada, France, Germany, Hungary, Ireland, South Africa, Spain and the UK
2) Participants: 1411 (Roflumilast 250 μg: 576, Roflumilast 500 μg: 555, Placebo: 280)

<PAGE>133